1. Introduction {#sec1}
===============

The non-condensed heterocyclic systems with thiazolidinone [@bib1] and pyrazoline [@bib2], [@bib3] moieties have emerged as powerful scaffolds in drug design. Among diazole-substituted 4-thiazolidinones highly active anticancer agents have been identified including inhibitors of necroptosis [@bib4], tumor necrosis factor α [@bib5] and tyrosine phosphatase [@bib6]. Our previous study, based on a hybrid pharmacophore approach, allowed to establish a number of patterns in the structure--activity relationship (SAR) context for 4-thiazolidinones with a pyrazoline fragment in 2, 3 and 4 positions of the thiazolidone cycle, which possessed antitumor activity [@bib7], [@bib8].

On the other hand, thiazolidinones and pyrazolines have occupied a unique position in the design and synthesis of novel biologically active agents that exert trypanocidal activity [@bib9], [@bib10], [@bib11], [@bib12], [@bib13]. The 2-thioxo-4-thiazolidinone-3-acetic acid derivatives were identified as inhibitors of *Trypanosoma brucei* dolicholphosphate mannose synthase [@bib11]. The 2-hydrazolyl-4-thiazolidinone-5-carboxylic acid derivatives have shown promising activity on the cruzipain protease [@bib12]. The most promising compound in series of aryl-4-oxothiazolylhydrazones was shown to be very active at non-cytotoxic concentrations in *in vitro* assays against *Trypanosoma cruzi* cell cultures and exhibited potency comparable with the reference compounds (IC~50~ (Y strain) = 0.3 μM) [@bib9]. Among pyrazoline derivatives, some novel compounds have been identified as inhibitors of the trypanosomal cysteine protease cruzain with IC~50~ of 40--230 nM [@bib13].

The antiviral activity of heteryl substituted 4-thiazolidinones is promising. Among thiazole--thiazolidine conjugates [@bib14] and non-condensed derivatives with thiazolidinone and pyridine [@bib15], [@bib16], [@bib17] or pyrimidine [@bib18], [@bib19], [@bib20] cycles, anti-HIV agents were identified. In addition, this group of compounds was active against hepatitis C virus [@bib21], Tobacco Mosaic virus [@bib22] and Vesicular stomatitis virus [@bib23]. Previously we also demonstrated the efficiency of certain pyrazoline--thiazolidinone conjugates on influenza viruses and SARS coronavirus [@bib24].

The present work is an extension of our ongoing efforts toward developing promising biologically active agents using a hybrid pharmacophore approach. We made the design ([Fig. 1](#fig1){ref-type="fig"} ) and synthesized hybrid compounds by linking the main structural unit of the 4-thiazolidinone ring system with the pyrazoline, and examined their antitumor, trypanocidal and antiviral activities *in vitro*. We have found two compounds from 5-pyrazoline substituted 4-thiazolidinones, which possessed a commensurate antitumor activity compared to the pyrazoline--thiazolidinone analogous compounds reported previously [@bib7], [@bib8] and evaluated anti-trypanosomal activity and antiviral activity of the synthesized compounds.Fig. 1Design of the non-condensed systems with the thiazolidinone and pyrazoline fragments.

2. Results and discussion {#sec2}
=========================

2.1. Chemistry {#sec2.1}
--------------

The general methods for synthesis of target thiazolidinone--pyrazoline conjugates are depicted in [Schemes 1](#sch1){ref-type="fig"} and [2](#sch2){ref-type="fig"} .Scheme 1Synthesis of 5-(3-naphthalen-2-yl-5-aryl-4,5-dihydropyrazol-1-yl)-thiazolidine-2,4-diones. Reagents, conditions and yields: (a) EtOH, reflux 1 h, 78--83%; (b) KOH, EtOH, reflux 5 h, 68--79%; (b) CH~2~O, EtOH, r.t. 1 h, 69--85%.Scheme 2Synthesis of 5-\[2-(3,5-diaryl-4,5-dihydropyrazol-1-yl)-2-oxoethylidene\]-thiazolidine-2,4-dione. Reagents, conditions and yields: (d) triethylamine, dioxane, heating to 70--80 °C, 15 min, 69--86%; (e) KOH, EtOH, reflux 5 h, 72--87%.

The starting 3,5-diaryl-4,5-dihydropyrazoles synthesized using known methods from appropriate chalcones [@bib25] easily reacted with 5-bromothiazolidine-2,4-dione [@bib26] yielding 5-(3-naphthalen-2-yl-5-aryl-4,5-dihydropyrazol-1-yl)-thiazolidine-2,4-dione **1a** and **1b**. It is known that chemical modification of the N3 position of thiazolidinone cycle has an essential influence on the antitumor activity [@bib27], [@bib28]. Relying on these observations we utilized potassium salt of 5-(3-naphthalen-2-yl-5-aryl-4,5-dihydropyrazol-1-yl)-thiazolidine-2,4-dione, generated *in situ*, in the reactions with 2-chloro-*N*-arylacetamides. Following the mentioned reaction the new N3-substituted non-condensed thiazolidinone--pyrazoline conjugates **2a**--**2c** were synthesized. Based on the Mannich reaction of **1a** and **1b** with secondary amines the thiazolidinone analogs **3a**--**3g** were obtained ([Scheme 1](#sch1){ref-type="fig"}).

Aiming at the detailed elaboration of SAR, especially the influence of the linking group of thiazolidinone--pyrazoline conjugates on the anticancer activity, 5-\[2-(3,5-diaryl-4,5-dihydropyrazol-1-yl)-2-oxoethylidene\]-thiazolidine-2,4-diones (**4a**--**4f**) were synthesized by the method, described previously [@bib29]. Reaction of 3,5-diaryl-4,5-dihydropyrazoles with (2,4-dioxothiazolidine-5-ylidene)-acetyl chloride [@bib27] afforded in excellent yield and purity the compounds **4a**--**4f**. Following the reaction of generated *in situ* potassium salts of **4b** and **4e** with 2-chloro-*N*-arylacetamides the group of N3-substituted 4-thiazolidinones **5a**--**5e** were synthesized ([Scheme 2](#sch2){ref-type="fig"}).

The data characterization of synthesized novel heterocyclic substituted thiazolidones are presented in [Experimental part](#sec4){ref-type="sec"}. Analytical and spectral data (^1^H NMR, ^13^C NMR) confirmed the structure of the synthesized compounds.

Protons CH~2~--CH of pyrazoline fragment in the ^1^H NMR spectra of synthesized compounds showed characteristic patterns of an AMX system. The proton (CH) of thiazolidinone core of **1a**--**1b**, **2a**--**2c** and **3a**--**3g** showed the broad singlet at *δ* ∼5.59--5.99 and the protons of the methylene group (CH~2~CO) of **2a**--**2c** and **5a**--**5e** appeared as a broad singlet at *δ* ∼4.44--4.49 ppm. In the ^1^H NMR spectra of the **1a**--**1b** and **4a**--**4f** NH proton of thiazolidinone cycle the broad singlet at *δ*∼12.20--12.72 was found.

2.2. *In vitro* evaluation of the anticancer activity {#sec2.2}
-----------------------------------------------------

Synthesized derivatives **1a**, **1b**, **2a**, **3a**--**3d**, **3f**, **4a**, **4d**, **4e**, **4f** and **5d** were selected by National Cancer Institute (NCI, Bethesda USA) Developmental Therapeutic Program (DTP) and evaluated at the concentration of 10^−5^ M toward a panel of approximately sixty cancer cell lines (<http://dtp.nci.nih.gov>). The human tumor cell lines were derived from nine different cancer types: leukemia, melanoma, lung, colon, central nervous system, ovarian, renal, prostate and breast cancers. Primary anticancer assays were performed according to the NCI protocol as described elsewhere [@bib30], [@bib31], [@bib32], [@bib33]. The compounds were added at a single concentration and the cell cultures were incubated for 48 h. The end point determinations were made with a protein binding dye, sulforhodamine B (SRB). The results for each compound are reported as the percent growth (GP%) of treated cells when compared to untreated control cells ([Table 1](#tbl1){ref-type="table"} ). The range of percent growth shows the lowest and the highest percent growth found among the different cancer cell lines.Table 1Anticancer screening data at the concentration of 10 μM.Comp60 Cell lines assay in 1 dose 10 μM concentrationMean growth %Range of growth %The most sensitive cell linesGrowth % of the most sensitive cell lines**1a**101.5577.50--113.87UO-31 (Renal Cancer)77.50**1b**104.8474.89--169.65HOP-92 (Non-Small Cell Lung Cancer)74.89**2a**99.2376.58--113.53UO-31 (Renal Cancer)76.58**3a**100.9469.54 to 112.74HOP-92 (Non-Small Cell Lung Cancer)69.54**3b**99.4967.47--122.33OVCAR-4 (Ovarian Cancer)67.47**3c**100.6782.16--126.20UO-31 (Renal Cancer)82.16**3d**102.9674.48--127.35UO-31 (Renal Cancer)74.48**3f**102.1276.37--131.30K-562 (Leukemia)76.37**4a**96.6439.09--147.38SR (Leukemia)39.09K-562 (Leukemia)58.20RPMI-8226 (Leukemia)58.85LOX IMVI (Melanoma):55.70**4d**60.11−27.33--160.47CCRF-CEM (Leukemia)19.50HL-60(TB) (Leukemia)−27.33K-562 (Leukemia)33.24MOLT-4 (Leukemia)16.47HOP-92 (Non-Small Cell Lung Cancer)37.75KM12 (Colon Cancer)29.89SF-295 (CNS Cancer)−13.37OVCAR-3 (Ovarian Cancer)36.41RXF 393 (Renal Cancer)31.39PC-3 (Prostate Cancer)33.62MCF7 (Breast Cancer)30.34T-47D (Breast Cancer)37.99**4e**99.7378.68--132.27T-47D (Breast Cancer)78.68**4f**51.05−5.27--109.26CCRF-CEM (Leukemia)16.67HL-60(TB) (Leukemia)13.51K-562 (Leukemia)24.64MOLT-4 (Leukemia)11.47RPMI-8226 (Leukemia)2.48SR (Leukemia)10.57NCI-H522 (Non-Small Cell Lung Cancer)23.21A549/ATCC (Non-Small Cell Lung Cancer)30.04NCI-H460 (Non-Small Cell Lung Cancer)25.93KM12 (Colon Cancer)25.76SF-295 (CNS Cancer)−5.27UACC-62 (Melanoma)32.77MDA-MB-435 (Melanoma)39.46PC-3 (Prostate Cancer)35.99MCF7 (Breast Cancer)34.41HS 578T (Breast Cancer)35.58BT-549 (Breast Cancer)34.25T-47D39.30**5d**97.9774.66--118.66CCRF-CEM (Leukemia)74.66

The most active compounds **4d** and **4f** were found to be effective against 12 and 18 cell lines, respectively, compound **4a** was found to be moderately effective against few cell lines, while the other compounds (**1a**, **1b**, **2a**, **3a**--**3d**, **3f**, **4e**, **5d**) did not show any activity ([Table 1](#tbl1){ref-type="table"}).

Finally, compounds **4d** and **4f** were selected for an advanced assay against a panel of approximately sixty tumor cell lines at 10-fold dilutions of five concentrations (100 μM, 10 μM, 1 μM, 0.1 μM and 0.01 μM) [@bib30], [@bib31], [@bib32], [@bib33]. The percentage of growth was evaluated spectrophotometrically versus controls not treated with test agents after 48-h exposure and using SRB protein assay to estimate cell viability or growth. Dose--response parameters were calculated for each cell line: GI~50~ -- molar concentration of the compound that inhibits 50% net cell growth; and TGI -- molar concentration of the compound leading to the total inhibition. Furthermore, a mean graph midpoints (MG_MID) were calculated for each of the parameters, giving an average activity parameter over all cell lines for the tested compound. For the MG_MID calculation, insensitive cell lines were included with the highest concentration tested ([Table 2](#tbl2){ref-type="table"} ).Table 2Anticancer activity against a panel of approximately sixty tumor cell lines from nine different cancer types at 10-fold dilutions of five concentrations.CompoundEnd point (μM)LeukemiaNSC lung cancerColon cancerCNS cancerMelanomaOvarian cancerRenal cancerProstate cancerBreast cancerMG_MID**4d**GI~50~3.287.915.737.578.0711.378.134.646.507.02TGI25.3142.0621.0124.1028.2179.2044.0431.4047.3038.07**4f**GI~50~2.143.523.534.094.089.794.664.612.994.38TGI7.3861.5963.2031.9945.8879.8353.25100.015.8550.99

The tested compounds showed inhibition activity (GI~50~ \< 10 μM) against 47 from 55 (**4d**) and 56 from 59 (**4f**) human tumor cells with average GI~50~/TGI values of 7.02 μM/38.07 μM (**4d**) and 4.38 μM/50.99 μM (**4f**) ([Table 2](#tbl2){ref-type="table"}). With regard to the sensitivity against some individual cell lines among several subpanel, the compounds **4d** and **4f** demonstrated a certain sensitivity profile toward the leukemia subpanel tumor cell lines with GI~50~ values range of 2.12--4.58 μM (**4d**) and 1.64--3.20 μM (**4f**) ([Table 3](#tbl3){ref-type="table"} ).Table 3The influence of compounds **4d** and **4f** on the growth of individual tumor cell lines (GI~50~ \< 5 μM).CompoundDiseaseCell lineGI~50~, μMTGI, μM**4d**LeukemiaCCRF-CEM2.8511.3LeukemiaRPMI-82262.126.91LeukemiaSR2.859.02LeukemiaHL-60(TB)3.359.14LeukemiaK-5624.58100.0NSC lung cancerHOP-624.8519.8NSC lung cancerNCI-H4604.1818.7Colon cancerHCT-1164.5616.4Colon cancerHCT-154.8524.6Colon cancerKM124.7615.3CNS cancerSF-2952.9910.0CNS cancerU2514.2916.6MelanomaLOX IMVI3.2117.9MelanomaMDA-MB-4353.9131.7MelanomaUACC-622.839.28Ovarian cancerOVCAR-33.1711.0Renal cancer786-02.9613.5Prostate CancerPC-34.6344.4Prostate CancerDU-1454.6418.4**4f**LeukemiaHL-60(TB)3.206.48LeukemiaK-5621.9011.2LeukemiaMOLT-41.647.41LeukemiaRPMI-82261.975.88LeukemiaSR1.985.92NSC lung cancerA549/ATCC3.06100.0NSC lung cancerHOP-921.179.72NSC lung cancerNCI-H322M2.89100.0NSC lung cancerNCI-H4601.894.70Colon cancerHCT-1163.0113.9Colon cancerHCT-152.41100.0CNS cancerSF-2952.459.12CNS cancerSF-5392.435.79CNS cancerU2512.5813.2MelanomaMDA-MB-4352.7016.5MelanomaSK-MEL-52.0922.5MelanomaUACC-622.6612.8Ovarian cancerOVCAR-32.9010.6Renal cancerA4981.415.38Prostate CancerPC-34.94100.0Prostate CancerDU-1454.27100.0Breast cancerMCF-72.5314.1Breast cancerHS 578T1.948.26Breast cancerBT-5492.167.75Breast cancerT-47D1.539.40

The SAR study revealed that: (1) the level of antitumor activity of active thiazolidinones with pyrazoline fragment in 5 position (**4d** and **4f**) is compatible with effectivity levels of heteryl substituted thiazolidones, described previously [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42]; (2) conjugation of pyrazoline and thiazolidinone cycles using oxomethylidene linking group (**4f**) allowed us to increase the activity, in comparison with the structurally related conjugate representative 5-(3-naphthalen-2-yl-5-aryl-4,5-dihydropyrazol-1-yl)-thiazolidine-2,4-dione **1b**; (3) introduction of the substituents in 3*N*-position of thiazolidine fragment did not have significant influence on the antitumor activity.

2.3. COMPARE analysis {#sec2.3}
---------------------

NCI\'s COMPARE algorithm [@bib30], [@bib31], [@bib32], [@bib33] allows to assume biochemical mechanisms of action of the novel compounds on the basis of their *in vitro* activity profiles when comparing with those of standard agents. We performed COMPARE computations for the compounds **4d** and **4f** against the NCI "Standard Agents" database at the GI~50~ and TGI levels ([Table 4](#tbl4){ref-type="table"} ). However, obtained Pearson correlation coefficients (PCC) did not allow to distinguish cytotoxicity mechanism of tested compounds with high probability. The compound **4d** showed the highest correlation at the GI~50~ level with dihydroorotate dehydrogenase inhibitor brequinar (PCC = 0.651) and compound **4f** -- with maytansine (RNA/DNA antimetabolite, PCC = 0.636).Table 4COMPARE analysis results for compounds **4d** and **4f**.CompoundEnd pointPCC[a](#tbl4fna){ref-type="table-fn"}TargetTarget vector NSCTarget mechanism of action[b](#tbl4fnb){ref-type="table-fn"}**4d**GI~50~0.651BrequinarS368390Dihydroorotate dehydrogenase inhibitor0.634Dichloroallyl lawsoneS126771DNA/RNA antimetabolite0.626TrimetrexateS352122Dihydrofolate reductase inhibitor0.62[l]{.smallcaps}-Cysteine analogS303861Reversible binding inhibitor of the human kinesin Eg5, antimitotic agent0.586Soluble Baker\'s AntifolS139105RNA/DNA antimetabolite0.568Glycoxalic acidS267213**4f**GI~50~0.636MaytansineS153858RNA/DNA antimetabolite0.573RhizoxinS749069Microtubule polymerization inhibitor0.550Macbecin IIS269148DNA antimetabolite[^1][^2]

2.4. Evaluation of antiviral activity {#sec2.4}
-------------------------------------

Antiviral activity of **1a**, **1b**, **2a**--**2c**, **3d** and **3e** was determined against SARS coronavirus (SARS CoV) and influenza types A and B viruses (Flu A, Flu B). The obtained results are summarized in [Table 5](#tbl5){ref-type="table"} .Table 5Antiviral activity of the synthesized compounds.CompoundVirusVirus strainEC~50~[a](#tbl5fna){ref-type="table-fn"} μMSD[b](#tbl5fnb){ref-type="table-fn"}CC~50~[c](#tbl5fnc){ref-type="table-fn"} μMSDSI[d](#tbl5fnd){ref-type="table-fn"}**1a**Flu A (H1N1)California/07/20099.826.2310.305.751.1Flu A (H3N2)Perth/16/20094.313.356.234.551.4Flu A (H5N1)Duck/MN/1525/817.900.4512.466.951.6Flu BFlorida/4/20064.552.638.385.751.8SARS CoVUrbani\>23.476.9523.476.950**1b**Flu A (H1N1)California/07/20094.273.084.503.321.0Flu A (H3N2)Perth/16/20092.840.713.080.711.0Flu A (H5N1)Duck/MN/1525/815.212.136.402.611.2Flu BFlorida/4/20063.081.664.982.131.6SARS CoVUrbani\>23.236.8723.236.870**2a**Flu A (H1N1)California/07/2009141.6640.73219.6090.321.6Flu A (H3N2)Perth/16/200953.1353.1374.3888.551.4Flu A (H5N1)Duck/MN/1525/8121.7820.01\>354.190\>16.3Flu BFlorida/4/200679.6970.84170.01141.682.1SARS CoVUrbani\>313.4670.84313.4670.840**2b**Flu A (H1N1)California/07/200954.4724.6073.8022.841.3Flu A (H3N2)Perth/16/2009\>13.356.6813.356.680Flu A (H5N1)Duck/MN/1525/8150.9633.3956.2328.121.1Flu BFlorida/4/200635.1436.9042.1735.141.3SARS CoVUrbani\>351.440\>351.4400**2c**Flu A (H1N1)California/07/2009119.64100.84176.04119.641.5Flu A (H3N2)Perth/16/200918.807.5225.6418.801.3Flu A (H5N1)Duck/MN/1525/81179.46111.09264.9294.001.5Flu BFlorida/4/200695.71164.08131.60158.951.4SARS CoVUrbani\>341.830\>341.8300**3d**Flu A (H1N1)California/07/200913.7016.3414.6915.681.1Flu A (H3N2)Perth/16/2009\>6.603.636.603.630Flu A (H5N1)Duck/MN/1525/81\>24.7624.7624.7624.760Flu BFlorida/4/200657.7875.9459.4375.941.0SARS CoVUrbani21.465.7834.6719.811.6**3e**Flu A (H1N1)California/07/20094.011.824.562.371.1Flu A (H3N2)Perth/16/2009\>2.370.732.370.730Flu A (H5N1)Duck/MN/1525/814.382.196.204.741.4Flu BFlorida/4/20064.014.208.3910.222.1SARS CoVUrbani\>16.783.4716.783.470RibavirinFlu A (H1N1)California/07/200923.752.46\>348.07122.85\>15Flu A (H3N2)Perth/16/200918.4311.88\>368.5469.61\>20Flu A (H5N1)Duck/MN/1525/8118.437.37\>323.5090.09\>20Flu BFlorida/4/20065.732.05\>405.3912.28\>69Oseltamirvir-carboxylateFlu A (H1N1)California/07/200918.9910.90\>35.170.0\>1.9Flu A (H3N2)Perth/16/20093.062.81\>35.170.0\>11Flu A (H5N1)Duck/MN/1525/810.110.007\>35.170.0\>326Flu BFlorida/4/20063.524.22\>35.170.0\>10M128533 Protease inhibitorSARS CoVUrbani1.561.18\>236.410.0\>152[^3][^4][^5][^6]

Although antiviral activity was evident, virus inhibition occurred at or near the cytotoxic concentration. The compounds showed insignificant activities against the four strains of influenza virus with the range levels of selectivity index from 1.0 to 2.1. Compound **2a** had moderate activity against the duck strain of influenza A with a 50% effective concentration (EC~50~) of 21.78 μM and selective index (SI) of \>16.3; but did not have significant activity against other influenza strains. The majority of the compounds showed no activity against SARS CoV. The positive control compounds ribavirin, oseltamivir carboxylate, and M128533 were active as expected in the assays.

2.5. *In vitro* evaluation of antitrypanosomal activity {#sec2.5}
-------------------------------------------------------

The compounds **1a**, **2b** and **2c** were selected in advanced *in vitro* assay against *Trypanosoma brucei brucei* (Tbb) and *Trypanosoma brucei gambiense* (Tbg). The dose--response curves with drug concentrations ranging from 10 μg/ml to 0.625 μg/ml are depicted on [Fig. 2](#fig2){ref-type="fig"} .Fig. 2The dose--response curves of compounds **1a**, **2b** and **2c** on *Trypanosoma brucei brucei* (Tbb) and *Trypanosoma brucei gambiense* (Tbg) growth.

The results showed a moderated activity of compounds ([Table 6](#tbl6){ref-type="table"} ) on both parasite strains, namely IC~50~ (Tbb) = 5.43--13.87 μM and IC~50~ (Tbg) = 2.53--6.66 μM.Table 6Anti-trypanosomal activity of 5-(3-naphthalen-2-yl-5-aryl-4,5-dihydropyrazol-1-yl)-thiazolidine-2,4-dione derivatives (**1a**, **2b**, **2c**).CompTrypanosoma B.B.Trypanosoma B.G.IC~50~, μMSDIC~50~, μMSD**1a**13.870.366.661.15**2b**5.430.092.530.12**2c**11.260.316.100.43Pentamidine0.00320.00030.00530.0009[^7]

3. Conclusions {#sec3}
==============

In the present paper new 4-thiazolidinone based conjugates with pyrazoline moiety at 5 position are described. Antitumor activity assay of thirteen synthesized compounds allowed us to identify highly active thiazolidinone--pyrazoline hybrids **4d** and **4f**, which demonstrated certain sensitivity profile toward the leukemia subpanel tumor cell lines with GI~50~ values range of 2.12--4.58 μM (**4d**) and 1.64--3.20 μM (**4f**). The antitrypanosomal and antiviral activities screening of 5-(3-naphthalen-2-yl-5-aryl-4,5-dihydropyrazol-1-yl)-thiazolidine-2,4-diones was carried out and demonstrated the promising influence of mentioned compounds on *T. brucei*, and no activity to minimal effect on SARS coronavirus and influenza types A and B viruses. Further investigations of such thiazolidinone derivatives could be interesting with the hope to get more selective anticancer, antiviral and antiprotozoal agents among thiazolidinone--pyrazoline hybrid analogs.

4. Experimental {#sec4}
===============

4.1. Materials and methods {#sec4.1}
--------------------------

The starting 3,5-diaryl-4,5-dihydro-1*H*-pyrazole [@bib25], 5-bromothiazolidine-2,4-dione [@bib26], and (2,4-dioxothiazolidine-5-ylidene)-acetyl chloride [@bib27] were obtained according to the methods described previously. Preparation of compounds **4a**--**4d** and **4f** was described in our previous report [@bib29].

Melting points were measured in open capillary tubes on a BŰCHI B-545 melting point apparatus and are uncorrected. The elemental analyses (C, H, N) were performed using the Perkin--Elmer 2400 CHN analyzer. Analyses indicated by the symbols of the elements or functions were within ±0.4% of the theoretical values. The ^1^H NMR spectra were recorded on Varian Gemini 400 MHz and ^13^C NMR spectra on Varian Mercury-400 100 MHz in DMSO-*d* ~6~ or DMSO-*d* ~6~ + CCl~4~ mixture using tetramethylsilane (TMS) as an internal standard. Chemical shifts are reported in ppm units with use of *δ* scale.

4.2. Chemistry {#sec4.2}
--------------

### 4.2.1. General procedure for synthesis of 5-(3-naphthalen-2-yl-5-aryl-4,5-dihydropyrazol-1-yl)-thiazolidine-2,4-diones (**1a**, **1b**) {#sec4.2.1}

A mixture of 50 mmol 5-bromothiazolidine-2,4-dione and 50 mmol of appropriate 3,5-diaryl-4,5-dihydropyrazole was refluxed in 100 ml of ethanol during 1 h. The crystalline products were separated by filtration, washed with ethanol, and dried. Recrystallization from acetic acid rendered desired products in pure form.

#### 4.2.1.1. 5-\[5-(4-Methoxyphenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-thiazolidine-2,4-dione (**1a**) {#sec4.2.1.1}

Yield 78%, mp 208--210 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 12.20 (s, 1H, NH), 8.08 (s, 1H, arom), 7.87--7.97 (m, 4H, arom), 7.55--7.58 (m, 2H, arom), 7.50 (d, 2H, *J* = 8.4 Hz, arom), 7.02 (d, 2H, *J* = 8.4 Hz, arom), 5.74 (s, 1H, CH, thiazol), 4.29 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 13.5, 10.1 Hz), 3.83 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 16.8, 10.1 Hz), 3.78 (s, 3H, OCH~3~), 3.16 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 16.8, 13.5 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 172.6 (C000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000O), 171.7 (CO), 159.9, 154.7 (CN), 133.9, 133.3, 130.1, 130.0, 129.6, 128.9, 128.7, 128.2, 127.5, 127.2, 127.0, 123.5, 114.8, 70.1 (CH), 66.1 ([C]{.ul}HCH~2~), 55.7 (OCH~3~), 42.2 (CH[C]{.ul}H~2~). Calcd. for C~23~H~19~N~3~O~3~S: C, 66.17; H, 4.59; N, 10.06; Found: C, 66.38; H, 4.77; N, 10.28%.

#### 4.2.1.2. 5-\[5-(4-Chlorophenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-thiazolidine-2,4-dione (**1b**) {#sec4.2.1.2}

Yield 83%, mp 218--220 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 12.21 (s, 1H, NH), 8.06 (s, 1H, arom), 7.81--7.97 (m, 4H, arom), 7.49--7.62 (m, 5H, arom), 7.42 (s, 1H, arom), 5.79 (s, 1H, CH, thiazol), 4.41 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 13.5, 10.3 Hz), 3.82 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 16.5, 10.3 Hz), 3.14 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 16.5, 13.5 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 172.5 (CO), 171.6 (CO), 154.6 (CN), 137.9, 133.9, 133.4, 133.2, 130.1, 129.3, 129.0, 128.9, 128.7, 128.2, 127.5, 127.2, 127.1, 123.6, 74.0 (CH), 69.4 ([C]{.ul}HCH~2~), 42.5 (CH[C]{.ul}H~2~). Calcd. for C~22~H~16~ClN~3~O~2~S: C, 62.63; H, 3.82; N, 9.96; Found: C, 62.48; H, 3.98; N, 9.75%.

### 4.2.2. General procedure for synthesis of 2-{5-\[5-aryl-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-2,4-dioxothiazolidin-3-yl}-*N*-arylacetamides (**2a**--**2c**) {#sec4.2.2}

A suspension of compound **1a** or **1b** (3 mmol) and potassium hydroxide (3 mmol) was stirred at r.t. during 5 min, later appropriate 2-chloro-*N*-arylacetamide (3.3 mmol) was added and the mixture was refluxed for 5 h in EtOH (10 ml). Obtained powders were filtered off, washed with ethanol and recrystallized with DMF:ethanol (1:2) mixtures.

#### 4.2.2.1. 2-{5-\[5-(4-Methoxyphenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-2,4-dioxothiazolidin-3-yl}-*N*-*p*-tolylacetamide (**2a**) {#sec4.2.2.1}

Yield 73%, mp 216--218 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 10.03 (s, 1H, NH), 8.14 (s, 1H, arom), 7.87--7.97 (m, 4H, arom), 7.55--7.58 (m, 2H, arom), 7.52 (d, 2H, *J* = 8.6 Hz, arom), 7.30 (d, 2H, *J* = 8.3 Hz, arom), 7.17 (d, 2Н, *J* = 8.3 Hz, arom), 7.03 (d, 2Н, *J* = 8.6 Hz, arom), 5.91 (s, 1H, CH, thiazol), 4.45 (br. s, 2H, CH~2~), 4.40 (dd, 1Н, [CH]{.ul} ~2~CН, *J* = 13.8, 10.5 Hz), 3.83 (dd, 1Н, [CH]{.ul} ~2~CН, *J* = 16.1, 10.5 Hz), 3.79 (s, 3H, OCH~3~), 3.19 (dd, 1Н, CН~2~ [CH]{.ul}, *J* = 16.1, 13.8 Hz), 2.28 (s, 3H, CH~3~). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 172.6 (CO), 171.7 (CO), 163.8 (CO), 159.9, 154.7 (CN), 133.9, 133.3, 132.7, 131.5, 130.8, 130.1, 130.0, 129.7, 129.6, 129.4, 128.7, 128.2, 127.5, 127.2, 127.0, 123.5, 114.8, 70.1 (CH), 66.1 ([C]{.ul}HCH~2~), 55.7 (OCH~3~), 44.1 (CH~2~), 42.2 (CH[C]{.ul}H~2~), 20.9 (CH~3~). Calcd. for C~32~H~28~N~4~O~4~S: C, 68.07; H, 5.00; N, 9.92; Found: C, 67.88; H, 5.15; N, 9.68%.

#### 4.2.2.2. 2-{5-\[5-(4-Chlorophenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-2,4-dioxothiazolidin-3-yl}-*N*-*p*-tolylacetamide (**2b**) {#sec4.2.2.2}

Yield 68%, mp 220--222 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 10.05 (s, 1H, NH), 7.99 (s, 1H, arom), 7.83--7.89 (m, 3H, arom), 7.63 (d, 2Н, *J* = 8.3 Hz, arom), 7.43--7.50 (m, 4H, arom), 7.07 (d, 2Н, *J* = 8.3 Hz, arom), 5.81 (s, 1H, CH, thiazol), 4.52 (dd, 1Н, [CH]{.ul} ~2~CН, *J* = 13.8, 9.9 Hz), 4.47 (br. s, 2H, CH~2~), 3.85 (dd, 1Н, [CH]{.ul} ~2~CН, *J* = 16.2, 9.9 Hz), 3.16 (dd, 1Н, CН~2~ [CH]{.ul}, *J* = 16.8, 13.8 Hz), 2.31 (s, 3H, CH~3~). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 172.5 (CO), 171.6 (CO), 164.0 (CO), 154.6 (CN), 137.9, 133.9, 133.4, 133.2, 132.7, 131.5, 130.8, 130.1, 129.7, 129.3, 129.0, 128.9, 128.7, 128.2, 127.5, 127.2, 127.1, 123.6, 74.0 (CH), 69.4 ([C]{.ul}HCH~2~), 44.1 (CH~2~), 42.5 (CH[C]{.ul}H~2~), 21.0 (CH~3~). Calcd. for C~31~H~25~ClN~4~O~3~S: C, 65.43; H, 4.43; N, 9.85; Found: C, 65.62; H, 4.61; N, 9.68%.

#### 4.2.2.3. 2-{5-\[5-(4-Chlorophenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-2,4-dioxothiazolidin-3-yl}-*N*-(4-methoxyphenyl)-acetamide (**2c**) {#sec4.2.2.3}

Yield 79%, mp 212--214 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 10.21 (s, 1H, NH), 8.10 (s, 1H, arom), 7.88--7.95 (m, 4H, arom), 7.49--7.63 (m, 8H, arom), 6.93 (d, 2Н, *J* = 8.6 Hz, arom), 5.99 (s, 1H, CH, thiazol), 4.50 (dd, 1Н, [CH]{.ul} ~2~CН, *J* = 13.3, 9.7 Hz), 4.45 (br. s, 2H, CH~2~), 3.85 (dd, 1Н, [CH]{.ul} ~2~CH, *J* = 16.8, 9.7 Hz), 3.72 (s, 3H, OCH~3~), 3.16 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 16.8, 13.3 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 170.8 (CO), 170.6 (CO), 163.6 (CO), 155.9, 154.6 (CN), 138.0, 133.9, 133.3, 133.2, 132.2, 130.1, 129.3, 129.0, 128.8, 128.6, 128.2, 127.5, 127.2, 127.1, 123.9, 121.2, 114.4, 72.6 (CH), 69.2 ([C]{.ul}HCH~2~), 55.7 (OCH~3~), 44.3 (CH~2~), 42.6 (CH[C]{.ul}H~2~). Calcd. for C~31~H~25~ClN~4~O~4~S: C, 63.64; H, 4.31; N, 9.58; Found: C, 63.79; H, 4.55; N, 9.71%.

### 4.2.3. General procedure for synthesis of 5-\[5-aryl-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-3-*R*-methylthiazolidine-2,4-diones (**3a**--**3g**) {#sec4.2.3}

A mixture of compound **1a** or **1b** (3 mmol), appropriate amine (3.3 mmol) and formaldehyde (3 mmol) was stirred at r.t. during 1 h in EtOH (10 ml). Obtained powders were filtered off, washed with ethanol and recrystallized with DMF:ethanol (1:2) mixtures.

#### 4.2.3.1. 5-\[5-(4-Methoxyphenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-3-piperidin-1-ylmethylthiazolidine-2,4-dione (**3a**) {#sec4.2.3.1}

Yield 75%, mp 202--204 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 7.94--7.97 (m, 2H, arom), 7.76--7.83 (m, 3H, arom), 7.49--7.51 (m, 4H, arom), 6.97 (d, 2H, *J* = 7.7 Hz, arom), 5.54 (s, 1H, CH, thiazol), 4.59 (br. s, 2H, NCH~2~N), 4.34 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 12.6, 9.9 Hz), 3.83 (s, 3H, OCH~3~), 3.75 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 16.4, 9.9 Hz), 3.15 (dd, 1H, CH~2~CH, *J* = 16.4, 12.6 Hz), 2.67--2.72 (m, 4H, 2\*CH~2~), 1.52--1.57 (m, 6H, 3\*CH~2~). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 170.8 (CO), 170.6 (CO), 159.9, 154.6 (CN), 133.9, 133.3, 130.0, 129.6, 129.5, 128.8, 128.4, 128.2, 127.5, 127.3, 127.2, 123.9, 114.7, 72.6 (CH), 70.0 ([C]{.ul}HCH~2~), 55.7 (OCH~3~), 51.7 (CH~2~), 42.2 (CH[C]{.ul}H~2~), 40.9, 40.8, 26.1. Calcd. for C~29~H~30~N~4~O~3~S: C, 67.68; H, 5.88; N, 10.89; Found: C, 67.49; H, 5.62; N, 10.72%.

#### 4.2.3.2. 5-\[5-(4-Methoxyphenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-3-morpholin-4-ylmethylthiazolidine-2,4-dione (**3b**) {#sec4.2.3.2}

Yield 85%, mp 195--196 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 8.13 (s, 1H, arom), 7.92--7.97 (m, 4H, arom), 7.52--7.56 (m, 2H, arom), 7.34 (d, 2H, *J* = 8.1 Hz, arom), 6.94 (d, 2H, *J* = 8.1 Hz, arom), 5.74 (s, 1H, CH, thiazol), 5.09 (br. s, 2H, NCH~2~N), 4.33 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 13.1, 9.7 Hz), 3.74--3.81 (m, 4H), 3.51--3.54 (m, 4H, 2\*CH~2~) 3.38 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 16.7, 13.1 Hz), 2.45--2.47 (m, 4H, 2\*CH~2~). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 172.5 (CO), 171.5 (CO), 159.1, 153.6 (CN), 133.8, 133.4, 130.1, 129.6, 129.5, 128.8, 128.6, 128.2, 127.5, 127.3, 127.1, 123.8, 114.8, 70.9 (CH), 69.6 ([C]{.ul}HCH~2~), 66.6, 62.9, 55.6 (OCH~3~), 50.7 (CH~2~), 41.0 (CH[C]{.ul}H~2~). Calcd. for C~28~H~28~N~4~O~4~S: C, 65.10; H, 5.46; N, 10.84; Found: C, 65.32; H, 5.69; N, 10.69%.

#### 4.2.3.3. 3-(4-Acetylpiperazin-1-ylmethyl)-5-\[5-(4-methoxyphenyl)-3-naphthalen-2-yl-4,5-dihydro-pyrazol-1-yl\]-thiazolidine-2,4-dione (**3c**) {#sec4.2.3.3}

Yield 79%, mp 185--187 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 7.84--7.88 (m, 5H, arom), 7.49--7.51 (m, 4H, arom), 6.97 (d, 2H, *J* = 7.6 Hz, arom), 5.59 (s, 1H, CH, thiazol), 4.70 (d, 1H, *J* = 12.9 Hz, NCH~2~N), 4.65 (d, 1H, *J* = 12.9 Hz, NCH~2~N), 4.33 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 12.9, 9.7 Hz), 3.73--3.83 (m, 4H), 3.44--3.46 (m, 4H, 2\*CH~2~) 3.15 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 15.8, 12.9 Hz), 2.69--2.80 (m, 4H, 2\*CH~2~), 1.99 (s, 3H, COCH~3~). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 172.6 (CO), 171.7 (CO), 168.8 (CO), 159.9, 154.7 (CN), 133.9, 133.3, 130.1, 130.0, 129.6, 128.9, 128.7, 128.2, 127.5, 127.2, 127.0, 123.5, 114.8, 70.1 (CH), 66.1 ([C]{.ul}HCH~2~), 63.0, 55.7 (OCH~3~), 51.0, 50.1, 46.1, 42.2 (CH[C]{.ul}H~2~), 41.2. Calcd. for C~30~H~31~N~5~O~4~S: C, 64.61; H, 5.60; N, 12.56; Found: C, 64.78; H, 5.46; N, 12.40%.

#### 4.2.3.4. 3-(4-Benzylpiperazin-1-ylmethyl)-5-\[5-(4-methoxyphenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-thiazolidine-2,4-dione (**3d**) {#sec4.2.3.4}

Yield 80%, mp 168--170 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 8.09 (s, 1H, arom), 7.79--7.80 (m, 4H, arom), 7.50--7.55 (m, 4H, arom), 7.19--7.28 (m, 5H, arom), 7.01 (d, 2H, *J* = 8.4 Hz, arom), 5.72 (s, 1H, CH, thiazol), 4.55 (br. s, 2H, NCH~2~N), 4.33 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 13.0, 9.8 Hz), 3.77--3.84 (m, 4H), 3.45--3.51 (m, 4H, 2\*CH~2~) 3.18 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 15.0, 13.0 Hz), 2.65--2.69 (m, 2H, CH~2~), 2.38--2.41 (m, 4H, 2\*CH~2~). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 172.2 (CO), 172.1 (CO), 159.9, 155.1 (CN), 133.9, 133.3, 130.1, 130.0, 129.6, 129.5, 128.9, 128.8, 128.6, 128.5, 128.1, 127.6, 127.3, 127.2, 127.1, 123.7, 114.8, 72.5 (CH), 69.9 ([C]{.ul}HCH~2~), 55.7 (OCH~3~), 55.6, 50.7, 42.3 (CH[C]{.ul}H~2~), 40.9. Calcd. for C~35~H~35~N~5~O~3~S: C, 69.40; H, 5.82; N, 11.56; Found: C, 69.23; H, 5.96; N, 11.40%.

#### 4.2.3.5. 5-\[5-(4-Chlorophenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-3-(4-ethylpiperazin-1-ylmethyl)-thiazolidine-2,4-dione (**3e**) {#sec4.2.3.5}

Yield 72%, mp 182--184 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 8.11 (s, 1H, arom), 7.92--7.96 (m, 4H, arom), 7.54--7.61 (m, 5H, arom), 7.43 (br. s, 1H, arom), 5.78 (s, 1H, CH, thiazol), 4.58 (d, 1H, *J* = 12.9 Hz, NCH~2~N), 4.54 (d, 1H, *J* = 12.9 Hz, NCH~2~N), 4.42 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 13.3, 10.0 Hz), 3.85 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 16.0, 10.0 Hz), 3.47--3.55 (m, 4H, 2\*CH~2~), 3.16 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 16.0, 13.3 Hz), 3.64--3.67 (m, 2H, CH~2~), 2.39--2.43 (m, 4H, 2\*CH~2~), 1.03 (t, 3H, *J* = 7.1 Hz, CH~3~). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 172.9 (CO), 171.7 (CO), 154.6 (CN), 137.9, 133.9, 133.3, 133.2, 130.1, 129.3, 128.9, 128.7, 128.6, 128.2, 127.6, 127.2, 127.1, 123.6, 74.0 (CH), 69.4 ([C]{.ul}HCH~2~), 62.8, 52.3, 51.9, 42.5 (CH[C]{.ul}H~2~), 40.9. Calcd. for C~29~H~30~ClN~5~O~2~S: C, 63.55; H, 5.52; N, 12.78; Found: C, 63.69; H, 5.38; N, 12.56%.

#### 4.2.3.6. 3-(4-Acetylpiperazin-1-ylmethyl)-5-\[5-(4-chlorophenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-thiazolidine-2,4-dione (**3f**) {#sec4.2.3.6}

Yield 79%, mp 211--212 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 8.02 (s, 1H, arom), 7.78--7.93 (m, 5H, arom), 7.61 (d, 2H, *J* = 7.8 Hz, arom), 7.50--7.54 (m, 4H, arom), 7.43 (br. s, 1H, arom), 5.80 (s, 1H, CH, thiazol), 4.62 (br. s, 2H, NCH~2~N), 4.66 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 13.0, 10.2 Hz), 3.88 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 15.9, 10.2 Hz), 3.44--3.55 (m, 4H, 2\*CH~2~), 3.16 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 15.9, 13.0 Hz), 2.60--2.66 (m, 4H, 2\*CH~2~), 2.00 (s, 3H, CH~3~). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 172.2 (CO), 172.1 (CO), 168.8 (CO), 155.0 (CN), 137.9, 133.9, 133.4, 133.2, 130.1, 129.3, 129.2, 128.9, 128.8, 128.2, 127.7, 127.5, 127.3, 123.2, 72.6 (CH), 69.2 ([C]{.ul}HCH~2~), 63.0, 51.0, 50.1, 46.1, 42.6 (CH[C]{.ul}H~2~), 41.2. Calcd. for C~29~H~28~ClN~5~O~3~S: C, 61.97; H, 5.02; N, 12.46; Found: C, 61.72; H, 5.21; N, 12.34%.

#### 4.2.3.7. 3-(4-Benzylpiperazin-1-ylmethyl)-5-\[5-(4-chlorophenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-thiazolidine-2,4-dione (**3g**) {#sec4.2.3.7}

Yield 69%, mp 194--196 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 8.06 (s, 1H, arom), 7.87--7.93 (m, 5H, arom), 7.60 (d, 2H, *J* = 8.1 Hz, arom), 7.40--7.54 (m, 4H, arom), 7.22--7.26 (m, 4H, arom), 5.79 (s, 1H, CH, thiazol), 4.45--4.56 (m, 3H), 3.86 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 16.8, 9.8 Hz), 3.47--3.54 (m, 4H, 2\*CH~2~), 3.28 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 16.8, 13.2 Hz), 2.56--2.68 (m, 2H, CH~2~), 2.32--2.41 (m, 4H, 2\*CH~2~). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 172.2 (CO), 172.1 (CO), 155.0 (CN), 137.9, 133.9, 133.4, 133.2, 130.5, 130.1, 129.3, 129.2, 128.9, 128.7, 128.6, 128.5, 128.1, 127.6, 127.4, 127.3, 127.2, 123.7, 72.6 (CH), 69.3 ([C]{.ul}HCH~2~), 63.0, 53.1, 50.1, 42.6 (CH[C]{.ul}H~2~), 41.0. Calcd. for C~34~H~32~ClN~5~O~2~S: C, 66.93; H, 5.29; N, 11.48; Found: C, 66.68; H, 5.10; N, 11.22%.

### 4.2.4. General procedure for synthesis of 5-\[2-(3,5-diaryll-4,5-dihydropyrazol-1-yl)-2-oxoethylidene\]-thiazolidine-2,4-diones (**4a**--**4f**) {#sec4.2.4}

A solution of (2,4-dioxothiazolidin-5-ylidene)-acetyl chloride (3 mmol) in 5 ml of dioxane was added to a mixture of appropriate 3,5-diaryl-4,5-dihydro-1*H*-pyrazole (3 mmol) and triethylamine (3 mmol) in 5 ml of dioxane and later was heated to 70--80 °C during 15 min, cooled and poured water (50 ml). Obtained powder was filtered off, washed with water and recrystallized with DMF:ethanol (1:2) mixtures.

#### 4.2.4.1. 5-{2-\[5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-thiazolidine-2,4-dione (**4a**) {#sec4.2.4.1}

Yield 75%, mp 240--242 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 12.64 (br. s, 1H, NH), 7.81--7.86 (m, 3H, arom), 7.48--7.51 (m, 3H, arom, CH), 7.14 (d, 2H, *J* = 8.6 Hz, arom), 6.87 (d, 2H, *J* = 8.6 Hz, arom), 5.59 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 11.2, 4.3 Hz), 3.93 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.3, 11.2 Hz), 3.70 (s, 3H, OCH~3~), 3.21 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.3, 4.3 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 171.3 (CO), 167.1 (CO), 160.9 (CO), 159.2, 157.4 (CN), 139.9, 133.8, 131.4, 131.0, 129.4, 127.6, 127.5, 117.8, 114.6, 60.2 ([C]{.ul}HCH~2~), 55.6 (OCH~3~), 42.7 (CH[C]{.ul}H~2~). Calcd. for C~21~H~17~N~3~O~4~S: C, 61.91; H, 4.21; N, 10.31; Found: C, 61.78; H, 4.08; N, 10.13%.

#### 4.2.4.2. 5-{2-\[5-(4-Chlorophenyl)-3-phenyl-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-thiazolidine-2,4-dione (**4b**) {#sec4.2.4.2}

Yield 86%, mp 250--252 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 12.72 (br. s, 1H, NH), 7.84--7.87 (m, 3H, arom), 7.50--7.54 (m, 3H, arom, CH), 7.41 (d, 2H, *J* = 8.1 Hz, arom), 7.28 (d, 2H, *J* = 8.1 Hz, arom), 5.68 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 11.4, 4.3 Hz), 3.97 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.0, 11.4 Hz), 3.29 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.0, 4.3 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 171.4 (CO), 167.1 (CO), 160.9 (CO), 157.7 (CN), 137.9, 133.4, 133.2, 131.2, 129.5, 129.3, 129.0, 127.4, 117.9, 116.0, 57.2 ([C]{.ul}HCH~2~), 41.6 (CH[C]{.ul}H~2~). Calcd. for C~20~H~14~ClN~3~O~3~S: C, 58.32; H, 3.43; N, 10.20; Found: C, 58.58; H, 3.28; N, 10.03%.

#### 4.2.4.3. 5-{2-\[5-(2-Hydroxyphenyl)-3-phenyl-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-thiazolidine-2,4-dione (**4c**) {#sec4.2.4.3}

Yield 82%, mp 232--234 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 12.67 (br. s, 1H, NH), 9.72 (s, 1H, OH), 7.80--7.85 (m, 3H, arom), 7.46--7.49 (m, 3H, arom, CH), 7.07 (t, 1H, *J* = 7.8 Hz, arom), 6.90 (d, 1H, *J* = 6.7 Hz, arom), 6.80 (d, 1H, *J* = 7.8 Hz, arom), 6.71 (t, 1H, *J* = 7.4 Hz, arom), 5.72 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 11.6, 4.6 Hz), 3.88 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 17.9, 11.6 Hz), 3.14 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 17.9, 4.6 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 171.4 (CO), 167.1 (CO), 160.9 (CO), 157.7 (CN), 154.7, 139.7, 131.2, 129.3, 128.9, 127.4, 127.0, 119.4, 117.9, 116.0, 57.2 ([C]{.ul}HCH~2~), 41.6 (CH[C]{.ul}H~2~). Calcd. for C~20~H~15~N~3~O~4~S: C, 61.06; H, 3.84; N, 10.68; Found: C, 61.27; H, 3.71; N, 10.53%.

#### 4.2.4.4. 5-{2-\[5-(2-Hydroxyphenyl)-3-(4-methoxyphenyl)-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-thiazolidine-2,4-dione (**4d**) {#sec4.2.4.4}

Yield 69%, mp 245--247 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 12.57 (br. s, 1H, NH), 10.08 (s, 1H, OH), 7.82 (s, 1H, CH), 7.76 (d, 2H, *J* = 8.6 Hz, arom), 7.24 (d, 1H, *J* = 8.5 Hz, arom), 6.99--7.04 (m, 3H, arom), 6.77 (d, 1H, *J* = 8.6 Hz, arom), 5.64 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 11.4, 4.8 Hz), 3.77--3.91 (m, 4H), 3.14 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.2, 4.8 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 171.3 (CO), 167.2 (CO), 162.7 (CO), 161.9, 160.8, 157.5 (CN), 154.2, 139.7, 131.6, 129.8, 129.5, 129.2, 123.6, 118.3, 117.9, 114.8, 110.5, 56.8 ([C]{.ul}HCH~2~), 55.9 (OCH~3~), 41.4 (CH[C]{.ul}H~2~). Calcd. for C~21~H~17~N~3~O~5~S: C, 59.57; H, 4.05; N, 9.92; Found: C, 59.73; H, 4.21; N, 9.78%.

#### 4.2.4.5. 5-{2-\[5-(4-Methoxyphenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-thiazolidine-2,4-dione (**4e**) {#sec4.2.4.5}

Yield 78%, mp 271--273 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 12.71 (br. s, 1H, NH), 8.27 (s, 1H, arom), 8.08 (d, 1H, *J* = 8.6 Hz, arom), 7.96--8.02 (m, 3H, arom), 7.87 (s, 1H, CH), 7.56--7.61 (m, 2H, arom), 7.18 (d, 2H, *J* = 8.3 Hz, arom), 6.89 (d, 2H, *J* = 8.3 Hz, arom), 5.64 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 11.4, 4.0 Hz), 4.03 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.0, 11.4 Hz), 3.72 (s, 3H, OCH~3~), 3.39 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.0, 4.0 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 171.4 (CO), 167.2 (CO), 160.9 (CO), 159.2, 157.5 (CN), 140.1, 134.4, 133.8, 133.2, 129.1, 128.9, 128.7, 128.6, 128.2, 128.1, 127.6, 127.4, 123.6, 117.7, 114.6, 60.3 ([C]{.ul}HCH~2~), 55.6 (OCH~3~), 42.7 (CH[C]{.ul}H~2~). Calcd. for C~25~H~19~N~3~O~4~S: C, 65.63; H, 4.19; N, 9.18; Found: C, 65.49; H, 4.03; N, 9.32%.

#### 4.2.4.6. 5-{2-\[5-(4-Chlorophenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-thiazolidine-2,4-dione (**4f**) {#sec4.2.4.6}

Yield 82%, mp 268--270 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 12.71 (br. s, 1H, NH), 8.27 (s, 1H, arom), 7.95--8.11 (m, 4H, arom), 7.88 (s, 1H, CH), 7.56--7.60 (m, 2H, arom), 7.40 (d, 2H, *J* = 8.5 Hz, arom), 7.29 (d, 2H, *J* = 8.5 Hz, arom), 5.71 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 11.8, 4.7 Hz), 4.07 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.2, 11.8 Hz), 3.40 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.2, 4.7 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 171.2 (CO), 167.1 (CO), 161.2 (CO), 157.4 (CN), 140.7, 140.3, 134.4, 133.2, 132.7, 129.2, 129.0, 128.9, 128.8, 128.4, 128.3, 128.2, 128.1, 127.4, 123.6, 117.6, 60.3 ([C]{.ul}HCH~2~), 42.6 (CH[C]{.ul}H~2~). Calcd. for C~24~H~16~ClN~3~O~3~S: C, 62.40; H, 3.49; N, 9.10; Found: C, 62.18; H, 3.62; N, 9.02%.

### 4.2.5. General procedure for synthesis of 2-{5-\[2-(3,5-diaryl-4,5-dihydropyrazol-1-yl)-2-oxoethylidene\]-2,4-dioxothiazolidin-3-yl}-*N*-arylacetamides (**5a**--**5e**) {#sec4.2.5}

A suspension of compound **4b** or **4f** (3 mmol) and potassium hydroxide (3 mmol) was stirred at r.t. during 5 min, later appropriate 2-chloro-*N*-arylacetamide (3.3 mmol) was added and the mixture was refluxed for 5 h in EtOH (10 ml). Obtained powders were filtered off, washed with ethanol and recrystallized with DMF:ethanol (1:2) mixtures.

#### 4.2.5.1. 2-(5-{2-\[5-(4-Chlorophenyl)-3-phenyl-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-2,4-dioxothiazolidin-3-yl)-*N*-*p*-tolylacetamide (**5a**) {#sec4.2.5.1}

Yield 76%, mp 234--236 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 10.07 (s, 1H, NH), 8.02 (s, 1H, COCH), 7.82--7.84 (m, 2H, arom), 7.39--7.46 (m, 5H, arom), 7.31 (d, 2H, *J* = 8.2 Hz, arom), 7.26 (d, 2H, *J* = 8.2 Hz, arom), 7.04 (d, 2H, *J* = 7.9 Hz, arom), 5.70 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 11.3, 4.2 Hz), 4.47 (s, 2H, CH~2~), 3.98 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.1, 11.3 Hz), 3.24 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 18.1, 4.2 Hz), 2.29 (s, 3H, CH~3~). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 170.1 (CO), 166.1 (CO), 163.8 (CO), 160.9 (CO), 157.8 (CN), 140.5, 137.5, 136.3, 133.2, 132.7, 131.5, 130.8, 129.7, 129.4, 129.3, 128.2, 127.6, 119.7, 119.1, 60.2 ([C]{.ul}HCH~2~), 44.1 (CH~2~), 42.7 (CH[C]{.ul}H~2~), 20.9 (CH~3~) Calcd. for C~29~H~23~ClN~4~O~4~S: C, 62.31; H, 4.15; N, 10.02; Found: C, 62.49; H, 4.00; N, 9.89%.

#### 4.2.5.2. 2-(5-{2-\[5-(4-Chlorophenyl)-3-phenyl-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-2,4-dioxothiazolidin-3-yl)-*N*-(4-methoxyphenyl)-acetamide (**5b**) {#sec4.2.5.2}

Yield 72%, mp 228--230 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 10.04 (s, 1H, NH), 8.02 (s, 1H, COCH), 7.82--7.84 (m, 2H, arom), 7.43--7.52 (m, 5H, arom), 7.32 (d, 2H, *J* = 7.7 Hz, arom), 7.26 (d, 2H, *J* = 7.7 Hz, arom), 6.79 (d, 2H, *J* = 8.6 Hz, arom), 5.69 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 11.6, 4.2 Hz), 4.44 (s, 2H, CH~2~), 3.98 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 17.8, 11.6 Hz), 3.75 (s, 3H, CH~3~), 3.24 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 17.8, 4.2 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 170.1 (CO), 166.1 (CO), 163.5 (CO), 160.9 (CO), 157.7 (CN), 156.0, 140.5, 137.5, 132.7, 131.9, 131.5, 130.8, 129.4, 129.3, 128.3, 127.6, 121.3, 119.1, 114.4, 60.2 ([C]{.ul}HCH~2~), 55.7 (OCH~3~), 44.1 (CH~2~), 42.7 (CH[C]{.ul}H~2~). Calcd. for C~29~H~23~ClN~4~O~5~S: C, 60.57; H, 4.03; N, 9.74; Found: C, 60.39; H, 3.88; N, 9.58%.

#### 4.2.5.3. 2-(5-{2-\[5-(4-Chlorophenyl)-3-phenyl-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-2,4-dioxothiazolidin-3-yl)-*N*-(4-chlorophenyl)-acetamide (**5c**) {#sec4.2.5.3}

Yield 79%, mp 289--290 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 10.51 (s, 1H, NH), 7.98 (s, 1H, COCH), 7.83--7.86 (m, 2H, arom), 7.48--7.58 (m, 5H, arom), 7.34--7.42 (m, 3H, arom), 7.28 (d, 2H, *J* = 8.3 Hz, arom), 5.69 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 11.2, 4.2 Hz), 4.49 (s, 2H, CH~2~), 3.97 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 17.5, 11.2 Hz), 3.25 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 17.5, 4.2 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 170.1 (CO), 165.1 (CO), 164.3 (CO), 160.9 (CO), 157.8 (CN), 140.5, 137.7, 137.4, 132.7, 131.5, 130.8, 129.4, 129.3, 129.2, 128.3, 127.9, 127.6, 121.3, 119.3, 60.2 ([C]{.ul}HCH~2~), 44.2 (CH~2~), 42.7 (CH[C]{.ul}H~2~). Calcd. for C~28~H~20~ClN~4~O~4~S: C, 58.04; H, 3.48; N, 9.67; Found: C, 58.19; H, 3.28; N, 9.45%.

#### 4.2.5.4. *N*-(4-Methoxyphenyl)-2-(5-{2-\[5-(4-methoxyphenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-2,4-dioxothiazolidin-3-yl)-acetamide (**5d**) {#sec4.2.5.4}

Yield 86%, mp 268--269 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 10.24 (s, 1H, NH), 8.29 (s, 1H, COCH), 8.00--8.09 (m, 5H, arom), 7.59 (br. s, 2H, arom), 7.46 (d, 2H, *J* = 6.4 Hz, arom), 7.21 (d, 2H, *J* = 6.4 Hz, arom), 6.90 (br. s, 3H, arom), 5.68 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 11.1, 4.2 Hz), 4.47 (s, 2H, CH~2~), 4.05 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 15.6, 11.1 Hz), 3.71 (s, 6H, 2\*OCH~3~), 3.42 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 15.6, 4.2 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 171.4 (CO), 167.2 (CO), 164.3 (CO), 160.9 (CO), 159.2, 157.5 (CN), 156.0, 140.1, 137.5, 134.4, 133.8, 133.2, 131.9, 129.1, 128.9, 128.7, 128.6, 128.2, 128.1, 127.6, 127.4, 123.6, 117.7, 114.6, 60.3 ([C]{.ul}HCH~2~), 55.7 (OCH~3~), 55.6 (OCH~3~), 44.1 (CH~2~), 42.7 (CH[C]{.ul}H~2~). Calcd. for C~34~H~28~N~4~O~6~S: C, 65.79; H, 4.55; N, 9.03; Found: C, 65.96; H, 4.32; N, 8.75%.

#### 4.2.5.5. *N*-(4-Chlorophenyl)-2-(5-{2-\[5-(4-methoxyphenyl)-3-naphthalen-2-yl-4,5-dihydropyrazol-1-yl\]-2-oxoethylidene}-2,4-dioxothiazolidin-3-yl)-acetamide (**5e**) {#sec4.2.5.5}

Yield 87%, mp 279--280 °C. ^1^H NMR (400 MHz, DMSO-*d* ~6~ + CCl~4~): *δ* 10.33 (s, 1H, NH), 8.09--8.14 (m, 3H, COCH, arom), 7.87--7.93 (m, 3H, arom), 7.53--7.58 (m, 4H, arom), 7.25 (d, 2H, *J* = 7.4 Hz, arom), 7.19 (d, 2H, *J* = 6.4 Hz, arom), 6.84 (d, 2H, *J* = 6.4 Hz, arom), 5.68 (dd, 1H, CH~2~ [CH]{.ul}, *J* = 12.1, 3.8 Hz), 4.48 (s, 2H, CH~2~), 4.03 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 16.6, 12.1 Hz), 3.76 (s, 3H, OCH~3~), 3.40 (dd, 1H, [CH]{.ul} ~2~CH, *J* = 16.6, 3.8 Hz). ^13^C NMR (100 MHz, DMSO-*d* ~6~): *δ* 170.2 (CO), 165.1 (CO), 164.3 (CO), 160.8 (CO), 159.2, 157.9 (CN), 137.8, 137.3, 134.4, 133.6, 133.2, 129.2, 129.1, 129.0, 128.8, 128.5, 128.2, 128.1, 127.9, 127.6, 127.4, 123.7, 121.4, 119.4, 114.7, 60.4 ([C]{.ul}HCH~2~), 55.6 (OCH~3~), 44.2 (CH~2~), 42.8 (CH[C]{.ul}H~2~). Calcd. for C~33~H~25~ClN~4~O~5~S: C, 63.41; H, 4.03; N, 8.96; Found: C, 63.59; H, 4.18; N, 9.09%.

4.3. Pharmacology {#sec4.3}
-----------------

### 4.3.1. Primary anticancer assay {#sec4.3.1}

Primary anticancer assay was performed on a panel of approximately sixty human tumor cell lines derived from nine neoplastic diseases, in accordance with the protocol of the Drug Evaluation Branch, National Cancer Institute, Bethesda [@bib30], [@bib31], [@bib32], [@bib33]. Tested compounds were added to the culture at a single concentration (10^−5^ M) and the cultures were incubated for 48 h. End point determinations were made with a protein binding dye, sulforhodamine B (SRB). Results for each tested compound were reported as the percent of growth of the treated cells when compared to the untreated control cells. The percentage growth was evaluated spectrophotometrically versus controls not treated with test agents. The cytotoxic and/or growth inhibitory effects of the most active selected compounds were tested *in vitro* against the full panel of human tumor cell lines at concentrations ranging from 10^−4^ to 10^−8^ M. 48-h continuous drug exposure protocol was followed and an SRB protein assay was used to estimate cell viability or growth.

Using absorbance measurements \[time zero (*Tz*), control growth in the absence of drug (*C*), and test growth in the presence of drug (*Ti*)\], the percentage growth was calculated for each drug concentration. Percentage growth inhibition was calculated as:$$\left\lbrack {\left( {Ti - Tz} \right)/\left( {C - Tz} \right)} \right\rbrack \times 100\mspace{9mu}\text{for}\mspace{9mu}\text{concentrations}\mspace{9mu}\text{for}\mspace{9mu}\text{which}\mspace{9mu} Ti \geq Tz\text{,}$$ $$\left\lbrack {\left( {Ti - Tz} \right)/{Tz}} \right\rbrack \times 100\mspace{9mu}\text{for}\mspace{9mu}\text{concentrations}\mspace{9mu}\text{for}\mspace{9mu}\text{which}\mspace{9mu} Ti < Tz\text{.}$$

Dose response parameters (GI~50~, TGI) were calculated for each compound. Growth inhibition of 50% (GI~50~) was calculated from \[(*Ti* − *Tz*)/(*C* − *Tz*)\] × 100 = 50, which is the drug concentration resulting in a 50% lower net protein increase in the treated cells (measured by SRB staining) as compared to the net protein increase seen in the control cells. The drug concentration resulting in total growth inhibition (TGI) was calculated from *Ti* = *Tz*. Values were calculated for each of these parameters if the level of activity was reached; however, if the effect was not reached or was excessive, the value for that parameter was expressed as more or less than the maximum or minimum concentration tested. The lowest values were obtained with the most sensitive cell lines. Compounds having GI~50~ values ≤100 μM were declared to be active.

### 4.3.2. Methods for assay of antiviral activity {#sec4.3.2}

Primary antiviral assay was performed on a respiratory viruses panel (Flu A (H1N1), Flu A (H3N2), Flu A (H5N1), Flu B, SARS CoV) [@bib43]. Compounds were diluted to 20 mg/ml in DMSO then eight half-log dilutions were prepared in MEM solution with 50 mg/ml gentamicin. Each dilution was added to 5 wells of a 96-well plate with 80--100% confluent cells, and three wells of each dilution were then infected with the test virus using a multiplicity of infection of \<0.006 CCID50 per cell for each virus. Two wells remained uninfected as toxicity controls. A known active compound was run in parallel as a control. After cytopathic effect (CPE) was observed microscopically, plates were stained with neutral red dye for approximately 2 h, then supernatant dye was removed from the wells and the incorporated dye was extracted in 50:50 Sorensen citrate buffer/ethanol and read on a spectrophotometer at 540 nm. The optical density of test wells was converted to percent of cell and virus controls, then the concentration of test compound required to inhibit viral CPE by 50% (EC~50~) was calculated by regression analysis. The concentration of compound that would cause 50% cytotoxicity in the uninfected cells was similarly calculated (CC~50~). EC~50~ and CC~50~ were presented in μM. The selective index (SI) is the CC~50~ divided by EC~50~.

### 4.3.3. Anti-trypanosomal activity assay {#sec4.3.3}

Bloodstream forms of *T. brucei brucei* strain 90-13 and *T. brucei gambiense* Feo strain were cultured in HMI9 medium supplemented with 10% FCS at 37 °C under an atmosphere of 5% CO~2~ [@bib44]. In all experiments, log-phase parasite cultures were harvested by centrifugation at 3000×*g* and immediately used. Drug assays were based on the conversion of a redox-sensitive dye (resazurin) to a fluorescent product by viable cells as previously described [@bib45]. Drug stock solutions were prepared in pure DMSO. *T. brucei* bloodstream forms (10^5^ cells/ml) were cultured in 96-well plates either in the absence or in the presence of different concentrations of inhibitors in a final volume of 200 μl. After a 72-h incubation, resazurin solution was added in each well at the final concentration of 45 μM and fluorescence was measured at 530 nm and 590 nm absorbance after a further 4-h incubation. The percentage of inhibition of parasite growth rate was calculated by comparing the fluorescence of parasites maintained in the presence of drug to that of in the absence of drug. DMSO was used as control. Concentration inhibiting 50% of parasite growth (IC~50~) was determined from the dose--response curve with a drug concentrations ranging from 10 μg/ml to 0.625 μg/ml and presented in μM. IC~50~ value is the mean +/− the standard deviation of three independent experiments.

We are grateful to Dr. V.L. Narayanan from Drug Synthesis and Chemistry Branch, National Cancer Institute, Bethesda, MD, USA, for *in vitro* evaluation of anticancer activity. Evaluations of compounds for antiviral activity were supported by funds from contract N01-AI-15435 from the Virology Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

[^1]: Only correlations with PCC ≥ 0.55 were selected, as significant.

[^2]: Putative mechanisms of action were identified with the use of literature sources.

[^3]: 50% Effective (virus-inhibitory) concentration.

[^4]: 50% Cytotoxic concentration, determined in uninfected cells.

[^5]: SD -- standard deviation.

[^6]: Selectivity index (CC~50~/EC~50~), derived from three independent experiments.

[^7]: IC~50~ value is the mean +/− the standard deviation (SD) of three independent experiments.
